<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01904864</url>
  </required_header>
  <id_info>
    <org_study_id>FE15929</org_study_id>
    <nct_id>NCT01904864</nct_id>
  </id_info>
  <brief_title>Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia</brief_title>
  <acronym>BESTIRON</acronym>
  <official_title>A Single-center, Double-blinded, Randomized, 12 Week, Superiority Study in Infants and Young Children to Compare the Efficacy of NovaFerrum® Versus Ferrous Sulfate in the Treatment of Nutritional Iron Deficiency Anemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gensavis Pharmaceuticals, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, controlled, double-blinded single center trial to compare the&#xD;
      efficacy of NovaFerrum® to ferrous sulfate for the treatment of nutritional iron deficiency&#xD;
      anemia (IDA) in infants and young children.&#xD;
&#xD;
      Hypothesis: NovaFerrum® has greater efficacy than ferrous sulfate in increasing hemoglobin&#xD;
      concentration during a twelve week course of treatment to subjects with iron deficiency&#xD;
      anemia.&#xD;
&#xD;
      Primary Aim:&#xD;
&#xD;
      To compare the efficacy of NovaFerrum® to ferrous sulfate for the treatment of nutritional&#xD;
      IDA in infants and young children as determined by increase in hemoglobin concentration.&#xD;
&#xD;
      Secondary Aims:&#xD;
&#xD;
        1. To compare the adverse effects of treatment for IDA between ferrous sulfate and&#xD;
           NovaFerrum®&#xD;
&#xD;
        2. To compare normalization of iron stores as demonstrated by laboratory measures of IDA&#xD;
           (ferritin, TIBC, reticulocyte hemoglobin content) between subjects treated with ferrous&#xD;
           sulfate or NovaFerrum®&#xD;
&#xD;
        3. To compare the adherence to study medication between subjects on ferrous sulfate and&#xD;
           NovaFerrum®&#xD;
&#xD;
        4. To demonstrate efficacy of a once daily dosing regimen in the treatment of nutritional&#xD;
           IDA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening/Baseline Assessment (Week 0):&#xD;
&#xD;
        -  History and Physical Examination:&#xD;
&#xD;
        -  Detailed history regarding medical disorders predisposing to iron deficiency and diet&#xD;
           (breast feeding, iron fortified formula, cow's milk), including total daily amount.&#xD;
&#xD;
        -  Review of existing medical records (including blood counts and iron studies) submitted&#xD;
           by primary care provider or recorded on Children's electronic medical record.&#xD;
&#xD;
        -  History of pica and/or other sequelae from iron deficiency.&#xD;
&#xD;
        -  Details regarding prior or current iron oral therapy (dose, preparation, timing,&#xD;
           response) or recent blood transfusions.&#xD;
&#xD;
        -  Comprehensive physical exam (PE) (baseline visit) consisting of vital signs, general,&#xD;
           HEENT, cardio-respiratory, abdominal, extremities and skin; Focused PE (Weeks 4 and 12)&#xD;
           consisting of vital signs, general, cardio-respiratory, abdominal and skin.&#xD;
&#xD;
        -  Laboratory (Only #3 below for research only, not standard of care):&#xD;
&#xD;
             1. Complete blood count (CBC), reticulocyte count and reticulocyte hemoglobin content.&#xD;
&#xD;
             2. Serum ferritin, iron and total body iron capacity (TIBC).&#xD;
&#xD;
      Treatment Interventions:&#xD;
&#xD;
        -  Patients who meet eligibility criteria and whose parents provide written informed&#xD;
           consent will be randomized in a 1:1 ratio to receive either ferrous sulfate drops (15&#xD;
           mg/ml) or NovaFerrum® drops (15 mg/ml).&#xD;
&#xD;
        -  Subjects will be assigned to receive a single daily dose of 3 mg/kg elemental iron.&#xD;
           Timing of study drug will be at bedtime.&#xD;
&#xD;
        -  As a part of standard care, patients will be advised to reduce cow milk intake to a&#xD;
           maximum 16 oz. daily and not to give any milk after medication administration. There&#xD;
           will be no other dietary modification prescribed by the study.&#xD;
&#xD;
        -  Other iron containing medications (including vitamins) will be discontinued.&#xD;
&#xD;
        -  Families will be asked to make a daily diary entry documenting administration and&#xD;
           adverse effects and return the diary at follow-up clinic visits.&#xD;
&#xD;
      Follow-up Phone Contact (Weeks 2, 6, 10 - not standard of care)&#xD;
&#xD;
      - Phone contact with parents will be made biweekly between scheduled visits (e.g. Weeks 2, 6,&#xD;
      and 10) to assess adverse effects, promote strict adherence and remind them of the next&#xD;
      scheduled visit.&#xD;
&#xD;
      Assessment During Follow-up Visits at Weeks 4, 8, and 12 after Initiation of Therapy&#xD;
      (Follow-up visits during weeks 4 and 12 are standard of care; Follow-up visit at week 8 is&#xD;
      for research only):&#xD;
&#xD;
        -  Review of interval history and diet by direct questioning of the parents and review of&#xD;
           diary regarding adherence, adverse effects of iron therapy (e.g., refusal to take,&#xD;
           spitting/vomiting, abdominal pain, constipation, black stools, stained teeth). The diary&#xD;
           will also contain distracter items to assess background &quot;noise&quot;.&#xD;
&#xD;
        -  Recording of other medications or intercurrent illnesses.&#xD;
&#xD;
        -  Laboratory studies at each follow-up visit: CBC with red blood cell (RBC) indices, (MCV,&#xD;
           RDW) reticulocyte count, reticulocyte hemoglobin content, serum ferritin, serum iron and&#xD;
           total iron binding capacity.&#xD;
&#xD;
        -  Blood lead measurement at week 4 (research only). Will repeated only if abnormal.&#xD;
&#xD;
        -  Focused physical exam at 4 and 12 week visits&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin Concentration Over Time</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary outcome will be the change in the peripheral blood hemoglobin concentration in grams/deciliter upon serial measurements at 0, 4, 8, and 12 weeks post-initiation of treatment. The primary analysis consists of a linear mixed regression model, which incorporates all subsequent time points into the model and includes treatment and time as covariates and patient random effects to account for correlation among longitudinal measurements from the same patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>NovaFerrum®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferrous Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elemental iron (NovaFerrum®)</intervention_name>
    <description>single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks</description>
    <arm_group_label>NovaFerrum®</arm_group_label>
    <other_name>Generic Name: polysaccharide iron vitamin mineral complex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elemental iron (Ferrous Sulfate)</intervention_name>
    <description>single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks</description>
    <arm_group_label>Ferrous Sulfate</arm_group_label>
    <other_name>Ferrous Sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 9 to &lt; 48 months&#xD;
&#xD;
          2. IDA documented by hematologic indices (hemoglobin, MCV, RDW, reticulocyte count,&#xD;
             reticulocyte hemoglobin content), serum ferritin, serum iron and total iron binding&#xD;
             capacity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Iron deficiency likely or definitely due to blood loss from the intestine or other&#xD;
             sites.&#xD;
&#xD;
          2. Evidence of response to recent/current oral iron therapy, as determined by increase in&#xD;
             hemoglobin by &gt; 1.0 gm/dL and MCV by 5 fL above measurements prior to iron therapy&#xD;
&#xD;
          3. History or evidence of intestinal malabsorption&#xD;
&#xD;
          4. History of prior intravenous iron therapy&#xD;
&#xD;
          5. Major co-morbidity such as a serious chronic medical condition unrelated to iron&#xD;
             deficiency apparent on history, physical examination, or laboratory tests&#xD;
&#xD;
          6. Other causes of anemia (sickle cell disease, thalassemia, other hemolytic anemia, bone&#xD;
             marrow failure, etc.) apparent by history, physical examination, and/or laboratory&#xD;
             tests.&#xD;
&#xD;
          7. High likelihood of suboptimal adherence by parents with study requirements (previous&#xD;
             missed clinic visits)&#xD;
&#xD;
          8. Inability to tolerate oral medications&#xD;
&#xD;
          9. History of birth at &lt; 30 weeks gestation&#xD;
&#xD;
         10. Other medical or social factors at discretion of treating physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Leavey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U Texas Southwestern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <results_first_submitted>August 15, 2017</results_first_submitted>
  <results_first_submitted_qc>August 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2017</results_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Patrick Leavey</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>randomized controlled trial</keyword>
  <keyword>iron medication</keyword>
  <keyword>Anemia</keyword>
  <keyword>Hematologic Disease</keyword>
  <keyword>Anemia, Iron deficiency</keyword>
  <keyword>anemia, nutritional</keyword>
  <keyword>ferrous sulfate</keyword>
  <keyword>NovaFerrum®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NovaFerrum® (Iron Polysaccharide Complex)</title>
          <description>Subjects randomized to this arm received a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation of an iron polysaccharide complex (NovaFerrum®), for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Ferrous Sulfate</title>
          <description>Subjects randomized to this arm received a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NovaFerrum® (Iron Polysaccharide Complex)</title>
          <description>Subjects randomized to this arm received a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation of an iron polysaccharide complex (NovaFerrum®), for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Ferrous Sulfate</title>
          <description>Subjects randomized to this arm received a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="11" upper_limit="34"/>
                    <measurement group_id="B2" value="22" lower_limit="10" upper_limit="37"/>
                    <measurement group_id="B3" value="23" lower_limit="10" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1 Race/ethnicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin Concentration Over Time</title>
        <description>The primary outcome will be the change in the peripheral blood hemoglobin concentration in grams/deciliter upon serial measurements at 0, 4, 8, and 12 weeks post-initiation of treatment. The primary analysis consists of a linear mixed regression model, which incorporates all subsequent time points into the model and includes treatment and time as covariates and patient random effects to account for correlation among longitudinal measurements from the same patients.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NovaFerrum® (Iron Polysaccharide Complex)</title>
            <description>Subjects randomized to this arm received a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation of an iron polysaccharide complex (NovaFerrum®), for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ferrous Sulfate</title>
            <description>Subjects randomized to this arm received a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Concentration Over Time</title>
          <description>The primary outcome will be the change in the peripheral blood hemoglobin concentration in grams/deciliter upon serial measurements at 0, 4, 8, and 12 weeks post-initiation of treatment. The primary analysis consists of a linear mixed regression model, which incorporates all subsequent time points into the model and includes treatment and time as covariates and patient random effects to account for correlation among longitudinal measurements from the same patients.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="1.6"/>
                    <measurement group_id="O2" value="7.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="1.4"/>
                    <measurement group_id="O2" value="10.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="1.3"/>
                    <measurement group_id="O2" value="11.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="1.2"/>
                    <measurement group_id="O2" value="11.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Change at 12 weeks compared</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NovaFerrum® (Iron Polysaccharide Complex)</title>
          <description>Subjects randomized to this arm received a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation of an iron polysaccharide complex (NovaFerrum®), for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Ferrous Sulfate</title>
          <description>Subjects randomized to this arm received a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Methemoglobinemia</sub_title>
                <description>One patient receiving ferrous sulfate experienced a transient episode of methemoglobinemia of unknown cause during week 4. The patient was successfully treated with methylene blue and continued in the study without recurrence.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>Patients reporting abdominal pain, vomiting, diarrhea, or constipation at any time point in the study.</description>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="40"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jacquelyn M. Powers, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <email>jacquelyn.powers@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

